Skip to main content
Top
Published in: Acta Neuropathologica 5/2018

Open Access 01-11-2018 | Review

Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease

Authors: Gary P. Morris, Ian A. Clark, Bryce Vissel

Published in: Acta Neuropathologica | Issue 5/2018

Login to get access

Abstract

The dominant hypothesis of Alzheimer’s disease (AD) aetiology, the neuropathological guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both research and in clinical practice, have been built around one possible causal factor, amyloid-β (Aβ). However, the causal link between Aβ and AD remains unproven. Here, in the context of a detailed assessment of historical and contemporary studies, we raise critical questions regarding the role of Aβ in the definition, diagnosis and aetiology of AD. We illustrate that a holistic view of the available data does not support an unequivocal conclusion that Aβ has a central or unique role in AD. Instead, the data suggest alternative views of AD aetiology are potentially valid, at this time. We propose that an unbiased way forward for the field, beyond the current Aβ-centric approach, without excluding a role for Aβ, is required to come to an accurate understanding of AD dementia and, ultimately, an effective treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Abner EL, Kryscio RJ, Schmitt FA, SantaCruz KS, Jicha GA, Lin Y et al (2011) “End-stage” neurofibrillary tangle pathology in preclinical Alzheimer’s disease: fact or fiction? J Alzheimers Dis 25(3):445–453PubMedPubMedCentralCrossRef Abner EL, Kryscio RJ, Schmitt FA, SantaCruz KS, Jicha GA, Lin Y et al (2011) “End-stage” neurofibrillary tangle pathology in preclinical Alzheimer’s disease: fact or fiction? J Alzheimers Dis 25(3):445–453PubMedPubMedCentralCrossRef
2.
go back to reference Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):270–279CrossRef Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):270–279CrossRef
3.
go back to reference Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C et al (2012) Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50(12):2880–2886PubMedPubMedCentralCrossRef Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C et al (2012) Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50(12):2880–2886PubMedPubMedCentralCrossRef
4.
go back to reference Andersen OM, Rudolph I-M, Willnow TE (2016) Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease. Acta Neuropathol 132(5):653–665PubMedPubMedCentralCrossRef Andersen OM, Rudolph I-M, Willnow TE (2016) Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease. Acta Neuropathol 132(5):653–665PubMedPubMedCentralCrossRef
5.
go back to reference Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, da Silva CG, Guimarães DM, Szczupak D et al (2013) Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 136(12):3738–3752PubMedPubMedCentralCrossRef Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, da Silva CG, Guimarães DM, Szczupak D et al (2013) Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 136(12):3738–3752PubMedPubMedCentralCrossRef
6.
go back to reference Atwood CS, Bowen RL, Smith MA, Perry G (2003) Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Rev 43(1):164–178PubMedCrossRef Atwood CS, Bowen RL, Smith MA, Perry G (2003) Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res Rev 43(1):164–178PubMedCrossRef
7.
go back to reference Baddeley M (2015) Herding, social influences and behavioural bias in scientific research: simple awareness of the hidden pressures and beliefs that influence our thinking can help to preserve objectivity. EMBO Rep 16(8):902–905PubMedPubMedCentralCrossRef Baddeley M (2015) Herding, social influences and behavioural bias in scientific research: simple awareness of the hidden pressures and beliefs that influence our thinking can help to preserve objectivity. EMBO Rep 16(8):902–905PubMedPubMedCentralCrossRef
8.
go back to reference Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL et al (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst) 6:108–121 Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL et al (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement (Amst) 6:108–121
9.
go back to reference Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE et al (2017) The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. J Neurol Neurosurg Psychiatry 88(11):982–994PubMedCrossRef Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE et al (2017) The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. J Neurol Neurosurg Psychiatry 88(11):982–994PubMedCrossRef
10.
go back to reference Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM et al (2017) The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement J Alzheimers Assoc 13(1):8–19CrossRef Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM et al (2017) The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement J Alzheimers Assoc 13(1):8–19CrossRef
11.
go back to reference Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9):795–804PubMedPubMedCentralCrossRef Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9):795–804PubMedPubMedCentralCrossRef
12.
go back to reference Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer’s Disease Centers, 2005–2010. J Neuropathol Exp Neurol 71(4):266–273PubMedCrossRef Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer’s Disease Centers, 2005–2010. J Neuropathol Exp Neurol 71(4):266–273PubMedCrossRef
13.
go back to reference Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al (2014) Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet 10(9):e1004606PubMedPubMedCentralCrossRef Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al (2014) Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet 10(9):e1004606PubMedPubMedCentralCrossRef
14.
go back to reference Behl C, Ziegler C (2017) Beyond amyloid—widening the view on Alzheimer’s disease. J Neurochem 143(4):394–395PubMedCrossRef Behl C, Ziegler C (2017) Beyond amyloid—widening the view on Alzheimer’s disease. J Neurochem 143(4):394–395PubMedCrossRef
15.
go back to reference Belleville S, Fouquet C, Duchesne S, Collins DL, Hudon C (2014) Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing. J Alzheimers Dis 42(Suppl 4):S375–S382PubMedCrossRef Belleville S, Fouquet C, Duchesne S, Collins DL, Hudon C (2014) Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing. J Alzheimers Dis 42(Suppl 4):S375–S382PubMedCrossRef
16.
go back to reference Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15:349PubMedCrossRef Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15:349PubMedCrossRef
17.
18.
go back to reference Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C et al (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci 110(47):E4502–E4509PubMedCrossRefPubMedCentral Benzinger TLS, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C et al (2013) Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci 110(47):E4502–E4509PubMedCrossRefPubMedCentral
19.
go back to reference Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging 19(3):173–189PubMedCrossRef Berchtold NC, Cotman CW (1998) Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging 19(3):173–189PubMedCrossRef
20.
go back to reference Bereczki E, Branca RM, Francis PT, Pereira JB, Baek JH, Hortobagyi T et al (2018) Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 141(2):582–595PubMedCrossRefPubMedCentral Bereczki E, Branca RM, Francis PT, Pereira JB, Baek JH, Hortobagyi T et al (2018) Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 141(2):582–595PubMedCrossRefPubMedCentral
21.
go back to reference Bessi V, Mazzeo S, Padiglioni S, Piccini C, Nacmias B, Sorbi S et al (2018) From subjective cognitive decline to Alzheimer’s disease: the predictive role of neuropsychological assessment, personality traits, and cognitive reserve. A 7-year follow-up study. J Alzheimers Dis 63(4):1523–1535PubMedCrossRef Bessi V, Mazzeo S, Padiglioni S, Piccini C, Nacmias B, Sorbi S et al (2018) From subjective cognitive decline to Alzheimer’s disease: the predictive role of neuropsychological assessment, personality traits, and cognitive reserve. A 7-year follow-up study. J Alzheimers Dis 63(4):1523–1535PubMedCrossRef
22.
go back to reference Bilgel M, An Y, Helphrey J, Elkins W, Gomez G, Wong DF et al (2018) Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain 141(8):2475–2485PubMedCentralCrossRefPubMed Bilgel M, An Y, Helphrey J, Elkins W, Gomez G, Wong DF et al (2018) Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain 141(8):2475–2485PubMedCentralCrossRefPubMed
23.
go back to reference Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114(512):797–811PubMedCrossRef Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114(512):797–811PubMedCrossRef
24.
go back to reference Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505–508PubMedCrossRef Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505–508PubMedCrossRef
25.
go back to reference Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA et al (2013) Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 74(3):478–489PubMedCrossRef Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA et al (2013) Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol 74(3):478–489PubMedCrossRef
26.
go back to reference Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA et al (2015) Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85(22):1930–1936PubMedPubMedCentralCrossRef Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA et al (2015) Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85(22):1930–1936PubMedPubMedCentralCrossRef
27.
go back to reference Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA (2018) Person-specific contribution of neuropathologies to cognitive loss in old age. Annals Neurol 83(1):74–83CrossRef Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA (2018) Person-specific contribution of neuropathologies to cognitive loss in old age. Annals Neurol 83(1):74–83CrossRef
28.
go back to reference Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRef Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRef
29.
go back to reference Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121(2):171–181PubMedCrossRef Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121(2):171–181PubMedCrossRef
30.
go back to reference Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11):960–969CrossRefPubMed Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11):960–969CrossRefPubMed
31.
go back to reference Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L et al (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener 9(1):53PubMedPubMedCentralCrossRef Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L et al (2014) SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener 9(1):53PubMedPubMedCentralCrossRef
32.
go back to reference Brothers HM, Gosztyla ML, Robinson SR (2018) The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci 10:118PubMedPubMedCentralCrossRef Brothers HM, Gosztyla ML, Robinson SR (2018) The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front Aging Neurosci 10:118PubMedPubMedCentralCrossRef
33.
go back to reference Cacace R, Sleegers K, Van Broeckhoven C (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement 12(6):733–748PubMedCrossRef Cacace R, Sleegers K, Van Broeckhoven C (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement 12(6):733–748PubMedCrossRef
34.
go back to reference Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR (2017) Alzheimer disease. Mayo Clin Proc 92(6):978–994PubMedCrossRef Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR (2017) Alzheimer disease. Mayo Clin Proc 92(6):978–994PubMedCrossRef
35.
go back to reference Castellani R, Perry G (2013) Molecular pathology of Alzheimer’s disease. Biota Publishing, Princeton Castellani R, Perry G (2013) Molecular pathology of Alzheimer’s disease. Biota Publishing, Princeton
36.
go back to reference Castellani RJ, Lee H-G, Zhu X, Perry G, Smith MA (2008) Alzheimer’s disease pathology as a host response. J Neuropathol Exp Neurol 67(6):523–531PubMedCrossRef Castellani RJ, Lee H-G, Zhu X, Perry G, Smith MA (2008) Alzheimer’s disease pathology as a host response. J Neuropathol Exp Neurol 67(6):523–531PubMedCrossRef
37.
go back to reference Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111(6):503–509PubMedCrossRef Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111(6):503–509PubMedCrossRef
38.
go back to reference Castellani RJ, Perry G (2014) The complexities of the pathology–pathogenesis relationship in Alzheimer disease. Biochem Pharmacol 88(4):671–676PubMedCrossRef Castellani RJ, Perry G (2014) The complexities of the pathology–pathogenesis relationship in Alzheimer disease. Biochem Pharmacol 88(4):671–676PubMedCrossRef
39.
go back to reference Castellani RJ, Smith MA (2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’. J Pathol 224(2):147–152PubMedCrossRef Castellani RJ, Smith MA (2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’. J Pathol 224(2):147–152PubMedCrossRef
40.
go back to reference Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol 14(1):169PubMedPubMedCentralCrossRef Castello MA, Jeppson JD, Soriano S (2014) Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol 14(1):169PubMedPubMedCentralCrossRef
42.
go back to reference Chen M, Mecca AP, Naganawa M et al (2018) Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2a positron emission tomographic imaging. JAMA Neurol Chen M, Mecca AP, Naganawa M et al (2018) Assessing synaptic density in alzheimer disease with synaptic vesicle glycoprotein 2a positron emission tomographic imaging. JAMA Neurol
44.
go back to reference Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F et al (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. NeuroImage Clin 2:356–365PubMedPubMedCentralCrossRef Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F et al (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. NeuroImage Clin 2:356–365PubMedPubMedCentralCrossRef
45.
go back to reference Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D et al (2010) Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67(3):317–324PubMed Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D et al (2010) Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67(3):317–324PubMed
46.
go back to reference Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I et al (2017) Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Mol Psychiatry 23(7):1666–1673PubMedCrossRef Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I et al (2017) Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Mol Psychiatry 23(7):1666–1673PubMedCrossRef
47.
go back to reference Clark IA, Alleva LM, Vissel B (2010) The roles of TNF in brain dysfunction and disease. Pharmacol Ther 128(3):519–548PubMedCrossRef Clark IA, Alleva LM, Vissel B (2010) The roles of TNF in brain dysfunction and disease. Pharmacol Ther 128(3):519–548PubMedCrossRef
48.
go back to reference Clark IA, Vissel B (2015) Amyloid beta: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br J Pharmacol 172(15):3714–3727PubMedPubMedCentralCrossRef Clark IA, Vissel B (2015) Amyloid beta: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br J Pharmacol 172(15):3714–3727PubMedPubMedCentralCrossRef
49.
go back to reference Clark IA, Vissel B (2016) Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflamm 13(1):236CrossRef Clark IA, Vissel B (2016) Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflamm 13(1):236CrossRef
50.
go back to reference Clark IA, Vissel B (2018) Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases. Br J Pharmacol 175(20):3859–3875PubMedPubMedCentralCrossRef Clark IA, Vissel B (2018) Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α-synuclein, amyloid-β and insulin resistance in neurodegenerative diseases. Br J Pharmacol 175(20):3859–3875PubMedPubMedCentralCrossRef
51.
go back to reference Clark LR, Racine AM, Koscik RL, Okonkwo OC, Engelman CD, Carlsson CM et al (2016) Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer’s Prevention study. Alzheimers Dement 12(7):805–814PubMedPubMedCentralCrossRef Clark LR, Racine AM, Koscik RL, Okonkwo OC, Engelman CD, Carlsson CM et al (2016) Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer’s Prevention study. Alzheimers Dement 12(7):805–814PubMedPubMedCentralCrossRef
52.
53.
go back to reference Cohen AD, McDade E, Christian B, Price J, Mathis C, Klunk W et al (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition. Alzheimers Dement 14(6):743–750PubMedCrossRefPubMedCentral Cohen AD, McDade E, Christian B, Price J, Mathis C, Klunk W et al (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition. Alzheimers Dement 14(6):743–750PubMedCrossRefPubMedCentral
54.
go back to reference Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Marti MJ et al (2013) Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72(12):1203–1212PubMedCrossRef Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Marti MJ et al (2013) Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72(12):1203–1212PubMedCrossRef
55.
go back to reference Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128(6):755–766PubMedPubMedCentralCrossRef Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128(6):755–766PubMedPubMedCentralCrossRef
56.
go back to reference Cummings J, Lee G, Ritter A, Zhong K (2018) Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement Transl Res Clin Interv 4:195–214CrossRef Cummings J, Lee G, Ritter A, Zhong K (2018) Alzheimer’s disease drug development pipeline: 2018. Alzheimers Dement Transl Res Clin Interv 4:195–214CrossRef
57.
go back to reference Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6(4):37PubMedPubMedCentralCrossRef Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6(4):37PubMedPubMedCentralCrossRef
58.
go back to reference Day GS, Musiek ES, Roe CM et al (2016) Phenotypic similarities between late-onset autosomal dominant and sporadic alzheimer disease: a single-family case-control study. JAMA Neurol 73(9):1125–1132PubMedPubMedCentralCrossRef Day GS, Musiek ES, Roe CM et al (2016) Phenotypic similarities between late-onset autosomal dominant and sporadic alzheimer disease: a single-family case-control study. JAMA Neurol 73(9):1125–1132PubMedPubMedCentralCrossRef
59.
go back to reference de la Torre J (2018) The vascular hypothesis of Alzheimer’s disease: a key to preclinical prediction of dementia using neuroimaging. J Alzheimers Dis 63(1):35–52PubMedCrossRef de la Torre J (2018) The vascular hypothesis of Alzheimer’s disease: a key to preclinical prediction of dementia using neuroimaging. J Alzheimers Dis 63(1):35–52PubMedCrossRef
60.
go back to reference de la Torre JC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3(3):184–190PubMedCrossRef de la Torre JC (2004) Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3(3):184–190PubMedCrossRef
61.
go back to reference de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C et al (2018) Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol 75(9):1062–1070PubMedCrossRefPubMedCentral de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C et al (2018) Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol 75(9):1062–1070PubMedCrossRefPubMedCentral
62.
go back to reference de Wilde MC, Overk CR, Sijben JW, Masliah E (2016) Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement J Alzheimers Assoc 12(6):633–644CrossRef de Wilde MC, Overk CR, Sijben JW, Masliah E (2016) Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement J Alzheimers Assoc 12(6):633–644CrossRef
63.
go back to reference Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA et al (2017) Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLOS Med 14(3):e1002258PubMedPubMedCentralCrossRef Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA et al (2017) Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLOS Med 14(3):e1002258PubMedPubMedCentralCrossRef
64.
go back to reference Dillman AA, Majounie E, Ding J, Gibbs JR, Hernandez D, Arepalli S et al (2017) Transcriptomic profiling of the human brain reveals that altered synaptic gene expression is associated with chronological aging. Sci Rep 7(1):16890PubMedPubMedCentralCrossRef Dillman AA, Majounie E, Ding J, Gibbs JR, Hernandez D, Arepalli S et al (2017) Transcriptomic profiling of the human brain reveals that altered synaptic gene expression is associated with chronological aging. Sci Rep 7(1):16890PubMedPubMedCentralCrossRef
65.
go back to reference Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369(4):341–350PubMedCrossRef Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369(4):341–350PubMedCrossRef
66.
go back to reference Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):311–321PubMedCrossRef Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):311–321PubMedCrossRef
67.
go back to reference Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 6(8):734–746PubMedCrossRef Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 6(8):734–746PubMedCrossRef
68.
go back to reference Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629PubMedCrossRef Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629PubMedCrossRef
69.
go back to reference Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S et al (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12(3):292–323PubMedCrossRefPubMedCentral Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S et al (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12(3):292–323PubMedCrossRefPubMedCentral
70.
71.
go back to reference Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 378(18):1691–1703PubMedCrossRefPubMedCentral Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 378(18):1691–1703PubMedCrossRefPubMedCentral
73.
go back to reference Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D et al (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 46(6):1592–1596PubMedCrossRef Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D et al (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, part XV. Neurology 46(6):1592–1596PubMedCrossRef
74.
go back to reference Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL et al (2017) 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer’s post-mortem brain. Front Aging Neurosci 9(195) Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL et al (2017) 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer’s post-mortem brain. Front Aging Neurosci 9(195)
75.
go back to reference Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS et al (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 6(226):226ra30PubMedPubMedCentralCrossRef Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS et al (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 6(226):226ra30PubMedPubMedCentralCrossRef
76.
go back to reference Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R et al (2018) Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 561(7721):137–140CrossRefPubMedPubMedCentral Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R et al (2018) Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature 561(7721):137–140CrossRefPubMedPubMedCentral
77.
go back to reference Fan Z, Brooks DJ, Okello A, Edison P (2017) An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain 140(3):792–803PubMedPubMedCentral Fan Z, Brooks DJ, Okello A, Edison P (2017) An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain 140(3):792–803PubMedPubMedCentral
78.
go back to reference Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA (2016) Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology 87(5):489–496PubMedPubMedCentralCrossRef Farfel JM, Yu L, Buchman AS, Schneider JA, De Jager PL, Bennett DA (2016) Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. Neurology 87(5):489–496PubMedPubMedCentralCrossRef
79.
go back to reference Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR et al (2017) Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol 74(7):830–838PubMedPubMedCentralCrossRef Farrell ME, Kennedy KM, Rodrigue KM, Wig G, Bischof GN, Rieck JR et al (2017) Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose-response relationship. JAMA Neurol 74(7):830–838PubMedPubMedCentralCrossRef
80.
go back to reference Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM et al (2009) Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc Natl Acad Sci USA 106(17):7209–7214PubMedCrossRefPubMedCentral Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM et al (2009) Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc Natl Acad Sci USA 106(17):7209–7214PubMedCrossRefPubMedCentral
81.
go back to reference Fiocco AJ, Kanaya AM, Lindquist KM, Harris TB, Satterfield S, Simonsick EM et al (2011) Plasma F(2)-isoprostane level and cognitive function over eight years in non-demented older adults: findings from the Health ABC Study. Prostaglandins Leukot Essent Fatty Acids 84(1–2):57–61PubMedCrossRef Fiocco AJ, Kanaya AM, Lindquist KM, Harris TB, Satterfield S, Simonsick EM et al (2011) Plasma F(2)-isoprostane level and cognitive function over eight years in non-demented older adults: findings from the Health ABC Study. Prostaglandins Leukot Essent Fatty Acids 84(1–2):57–61PubMedCrossRef
82.
go back to reference Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM et al (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred a cross-sectional study. JAMA Neurol 72(3):316–324PubMedPubMedCentralCrossRef Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM et al (2015) Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred a cross-sectional study. JAMA Neurol 72(3):316–324PubMedPubMedCentralCrossRef
83.
go back to reference Flier FJ, De Vries Robbé PF (1999) Nosology and causal necessity; the relation between defining a disease and discovering its necessary cause. Theor Med Bioeth 20(6):577–588PubMedCrossRef Flier FJ, De Vries Robbé PF (1999) Nosology and causal necessity; the relation between defining a disease and discovering its necessary cause. Theor Med Bioeth 20(6):577–588PubMedCrossRef
84.
go back to reference Fotiadis P, van Rooden S, van der Grond J, Schultz A, Martinez-Ramirez S, Auriel E et al (2016) Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol 15(8):811–819PubMedPubMedCentralCrossRef Fotiadis P, van Rooden S, van der Grond J, Schultz A, Martinez-Ramirez S, Auriel E et al (2016) Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurol 15(8):811–819PubMedPubMedCentralCrossRef
85.
go back to reference Furcila D, DeFelipe J, Alonso-Nanclares L (2018) A study of amyloid-beta and phosphotau in plaques and neurons in the hippocampus of Alzheimer’s disease patients. J Alzheimers Dis 64(2):417–435PubMedPubMedCentralCrossRef Furcila D, DeFelipe J, Alonso-Nanclares L (2018) A study of amyloid-beta and phosphotau in plaques and neurons in the hippocampus of Alzheimer’s disease patients. J Alzheimers Dis 64(2):417–435PubMedPubMedCentralCrossRef
86.
go back to reference Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C et al (2011) Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134(12):3694–3704PubMedCentralCrossRef Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C et al (2011) Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134(12):3694–3704PubMedCentralCrossRef
88.
go back to reference Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (Lond, Engl) 388(10062):2873–2884CrossRef Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH et al (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (Lond, Engl) 388(10062):2873–2884CrossRef
89.
go back to reference Giacobini E, Gold G (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nat Rev Neurol 9:677PubMedCrossRef Giacobini E, Gold G (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nat Rev Neurol 9:677PubMedCrossRef
91.
go back to reference Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3):1131–1135PubMedCrossRef Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3):1131–1135PubMedCrossRef
92.
go back to reference Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–890PubMedCrossRef Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–890PubMedCrossRef
93.
go back to reference Gomez-Isla T, Hollister R, West H, Mui S et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41(1):17–24PubMedCrossRef Gomez-Isla T, Hollister R, West H, Mui S et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol 41(1):17–24PubMedCrossRef
94.
go back to reference Gonneaud J, Chételat G (2018) Which is to blame for cognitive decline in ageing: amyloid deposition, neurodegeneration or both? Brain 141(8):2237–2241PubMedCrossRef Gonneaud J, Chételat G (2018) Which is to blame for cognitive decline in ageing: amyloid deposition, neurodegeneration or both? Brain 141(8):2237–2241PubMedCrossRef
95.
go back to reference Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S et al (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol 17(3):241–250PubMedCrossRefPubMedCentral Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S et al (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol 17(3):241–250PubMedCrossRefPubMedCentral
96.
go back to reference Gosztyla ML, Brothers HM, Robinson SR (2018) Alzheimer’s amyloid-beta is an antimicrobial peptide: a review of the evidence. J Alzheimers Dis 62(4):1495–1506PubMedCrossRef Gosztyla ML, Brothers HM, Robinson SR (2018) Alzheimer’s amyloid-beta is an antimicrobial peptide: a review of the evidence. J Alzheimers Dis 62(4):1495–1506PubMedCrossRef
99.
go back to reference Hardardottir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, Grunfeld C et al (1994) Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Investig 94(3):1304–1309PubMedCrossRefPubMedCentral Hardardottir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, Grunfeld C et al (1994) Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Investig 94(3):1304–1309PubMedCrossRefPubMedCentral
100.
go back to reference Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102(4):355–363PubMed Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102(4):355–363PubMed
101.
go back to reference Harris SA, Harris EA (2015) Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer’s disease. J Alzheimers Dis 48(2):319–353PubMedPubMedCentralCrossRef Harris SA, Harris EA (2015) Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer’s disease. J Alzheimers Dis 48(2):319–353PubMedPubMedCentralCrossRef
102.
103.
go back to reference Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT (2018) Fluid and imaging biomarkers for Alzheimer’s disease: where we stand and where to head to. Exp Gerontol 107:169–177PubMedCrossRefPubMedCentral Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nóbrega OT (2018) Fluid and imaging biomarkers for Alzheimer’s disease: where we stand and where to head to. Exp Gerontol 107:169–177PubMedCrossRefPubMedCentral
104.
go back to reference Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R et al (2013) Putting the Alzheimer’s cognitive test to the test II: Rasch measurement theory. Alzheimers Dement J Alzheimers Assoc 9(1):S10–S20CrossRef Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R et al (2013) Putting the Alzheimer’s cognitive test to the test II: Rasch measurement theory. Alzheimers Dement J Alzheimers Assoc 9(1):S10–S20CrossRef
105.
go back to reference Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM et al (2011) Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435PubMedPubMedCentralCrossRef Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM et al (2011) Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435PubMedPubMedCentralCrossRef
106.
go back to reference Honer WG (2003) Pathology of presynaptic proteins in Alzheimer’s disease: more than simple loss of terminals. Neurobiol Aging 24(8):1047–1062PubMedCrossRef Honer WG (2003) Pathology of presynaptic proteins in Alzheimer’s disease: more than simple loss of terminals. Neurobiol Aging 24(8):1047–1062PubMedCrossRef
107.
go back to reference Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M et al (2018) Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 378(4):321–330PubMedCrossRef Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M et al (2018) Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 378(4):321–330PubMedCrossRef
108.
go back to reference Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 8(1):1–13CrossRef Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 8(1):1–13CrossRef
109.
go back to reference Hyman BT, Trojanowski JQ (1997) Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097PubMedCrossRef Hyman BT, Trojanowski JQ (1997) Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56(10):1095–1097PubMedCrossRef
110.
go back to reference Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL et al (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s disease. NeuroImage Clin 17:452–464PubMedCrossRef Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL et al (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s disease. NeuroImage Clin 17:452–464PubMedCrossRef
111.
go back to reference Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P et al (2009) The Nun Study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73(9):665–673PubMedPubMedCentralCrossRef Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P et al (2009) The Nun Study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73(9):665–673PubMedPubMedCentralCrossRef
112.
go back to reference Iacono D, Resnick SM, O’Brien R, Zonderman AB, An Y, Pletnikova O et al (2014) Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 73(4):295–304PubMedCrossRef Iacono D, Resnick SM, O’Brien R, Zonderman AB, An Y, Pletnikova O et al (2014) Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol 73(4):295–304PubMedCrossRef
113.
go back to reference Iqbal K, Flory M, Soininen H (2013) Clinical symptoms and symptom signatures of Alzheimer’s disease subgroups. J Alzheimers Dis 37(3):475–481PubMedCrossRef Iqbal K, Flory M, Soininen H (2013) Clinical symptoms and symptom signatures of Alzheimer’s disease subgroups. J Alzheimers Dis 37(3):475–481PubMedCrossRef
114.
go back to reference Iqbal K, Liu F, Gong C-X (2015) Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12:15PubMedCrossRef Iqbal K, Liu F, Gong C-X (2015) Tau and neurodegenerative disease: the story so far. Nat Rev Neurol 12:15PubMedCrossRef
115.
go back to reference Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC (2016) The Alzheimer’s Disease Neuroimaging, I. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 7:11934PubMedPubMedCentralCrossRef Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC (2016) The Alzheimer’s Disease Neuroimaging, I. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 7:11934PubMedPubMedCentralCrossRef
116.
go back to reference Itzhaki RF, Lathe R (2018) Herpes viruses and senile dementia: first population evidence for a causal link. J Alzheimers Dis 64(2):363–366PubMedCrossRef Itzhaki RF, Lathe R (2018) Herpes viruses and senile dementia: first population evidence for a causal link. J Alzheimers Dis 64(2):363–366PubMedCrossRef
117.
118.
go back to reference Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539–547PubMedPubMedCentralCrossRef Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539–547PubMedPubMedCentralCrossRef
119.
go back to reference Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562PubMedPubMedCentralCrossRef Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562PubMedPubMedCentralCrossRef
120.
go back to reference Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207–216PubMedPubMedCentralCrossRef Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207–216PubMedPubMedCentralCrossRef
121.
go back to reference Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P et al (2013) Brain beta-amyloid load approaches a plateau. Neurology 80(10):890–896PubMedPubMedCentralCrossRef Jack CR Jr, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P et al (2013) Brain beta-amyloid load approaches a plateau. Neurology 80(10):890–896PubMedPubMedCentralCrossRef
122.
go back to reference Jack CR, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB et al (2016) Suspected non-Alzheimer disease pathophysiology—concept and controversy. Nat Rev Neurol 12(2):117–124PubMedPubMedCentralCrossRef Jack CR, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB et al (2016) Suspected non-Alzheimer disease pathophysiology—concept and controversy. Nat Rev Neurol 12(2):117–124PubMedPubMedCentralCrossRef
123.
go back to reference Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol 12(2):207–216PubMedPubMedCentralCrossRef Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Update on hypothetical model of Alzheimer’s disease biomarkers. Lancet Neurol 12(2):207–216PubMedPubMedCentralCrossRef
124.
go back to reference Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132(5):1355–1365PubMedPubMedCentralCrossRef Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132(5):1355–1365PubMedPubMedCentralCrossRef
125.
go back to reference Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ et al (2011) Evidence for ordering of Alzheimer’s disease biomarkers. Arch Neurol 68(12):1526–1535PubMedPubMedCentralCrossRef Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ et al (2011) Evidence for ordering of Alzheimer’s disease biomarkers. Arch Neurol 68(12):1526–1535PubMedPubMedCentralCrossRef
126.
go back to reference Jack JCR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P et al (2018) Longitudinal tau PET in ageing and Alzheimer’s disease. Brain 141(5):1517–1528PubMedPubMedCentralCrossRef Jack JCR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P et al (2018) Longitudinal tau PET in ageing and Alzheimer’s disease. Brain 141(5):1517–1528PubMedPubMedCentralCrossRef
127.
go back to reference Jagust W (2016) Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain 139(1):23–30PubMedCrossRef Jagust W (2016) Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain 139(1):23–30PubMedCrossRef
128.
go back to reference James AM (2012) The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res 9(6):621–627CrossRef James AM (2012) The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res 9(6):621–627CrossRef
129.
go back to reference Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19):1924–1938PubMedPubMedCentralCrossRef Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19):1924–1938PubMedPubMedCentralCrossRef
130.
go back to reference Jansen WJ, Ossenkoppele R, Tijms BM et al (2018) Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry 75(1):84–95PubMedCrossRef Jansen WJ, Ossenkoppele R, Tijms BM et al (2018) Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry 75(1):84–95PubMedCrossRef
131.
go back to reference John H (2017) The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”. FEBS J 284(7):1040–1044CrossRef John H (2017) The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”. FEBS J 284(7):1040–1044CrossRef
132.
go back to reference Johnson VE, Stewart W, Smith DH (2010) Traumatic brain injury and amyloid-β pathology: a link to Alzheimer’s disease? Nat Rev Neurosci 11(5):361–370PubMedPubMedCentralCrossRef Johnson VE, Stewart W, Smith DH (2010) Traumatic brain injury and amyloid-β pathology: a link to Alzheimer’s disease? Nat Rev Neurosci 11(5):361–370PubMedPubMedCentralCrossRef
133.
go back to reference Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al (2012) A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488:96PubMedCrossRef Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al (2012) A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488:96PubMedCrossRef
136.
go back to reference Karran E, De Strooper B (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139(Suppl 2):237–252PubMedCrossRef Karran E, De Strooper B (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139(Suppl 2):237–252PubMedCrossRef
137.
go back to reference Katzman R (1976) The prevalence and malignancy of alzheimer disease: a major killer. Arch Neurol 33(4):217–218PubMedCrossRef Katzman R (1976) The prevalence and malignancy of alzheimer disease: a major killer. Arch Neurol 33(4):217–218PubMedCrossRef
139.
go back to reference Kenney K, Iacono D, Edlow BL, Katz DI, Diaz-Arrastia R, Dams-O’Connor K et al (2018) Dementia after moderate-severe traumatic brain injury: coexistence of multiple proteinopathies. J Neuropathol Exp Neurol 77(1):50–63PubMedCrossRef Kenney K, Iacono D, Edlow BL, Katz DI, Diaz-Arrastia R, Dams-O’Connor K et al (2018) Dementia after moderate-severe traumatic brain injury: coexistence of multiple proteinopathies. J Neuropathol Exp Neurol 77(1):50–63PubMedCrossRef
140.
go back to reference Kenney K, Qu BX, Lai C, Devoto C, Motamedi V, Walker WC et al (2018) Higher exosomal phosphorylated tau and total tau among veterans with combat-related repetitive chronic mild traumatic brain injury. Brain Inj 32(10):1276–1284PubMedCrossRef Kenney K, Qu BX, Lai C, Devoto C, Motamedi V, Walker WC et al (2018) Higher exosomal phosphorylated tau and total tau among veterans with combat-related repetitive chronic mild traumatic brain injury. Brain Inj 32(10):1276–1284PubMedCrossRef
141.
go back to reference Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P et al (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72(11):1275–1280PubMedPubMedCentralCrossRef Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P et al (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72(11):1275–1280PubMedPubMedCentralCrossRef
142.
go back to reference Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C et al (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther 7(1):59PubMedPubMedCentralCrossRef Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C et al (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther 7(1):59PubMedPubMedCentralCrossRef
143.
144.
go back to reference Khachaturian ZS (2011) Revised criteria for diagnosis of Alzheimer’s disease: national Institute on Aging-Alzheimer’s Association diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):253–256CrossRef Khachaturian ZS (2011) Revised criteria for diagnosis of Alzheimer’s disease: national Institute on Aging-Alzheimer’s Association diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):253–256CrossRef
145.
go back to reference Klunemann HH, Fronhofer W, Wurster H, Fischer W, Ibach B, Klein HE (2002) Alzheimer’s second patient: Johann F. and his family. Ann Neurol 52(4):520–523PubMedCrossRef Klunemann HH, Fronhofer W, Wurster H, Fischer W, Ibach B, Klein HE (2002) Alzheimer’s second patient: Johann F. and his family. Ann Neurol 52(4):520–523PubMedCrossRef
146.
go back to reference Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ et al (2013) Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 73(4):472–480PubMedPubMedCentralCrossRef Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ et al (2013) Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 73(4):472–480PubMedPubMedCentralCrossRef
147.
go back to reference Kraepelin E (1909-1915) Psychiatrie: Ein Lehrbuch für Studirende und Aerzte, 8th edn. Leipzig, Barth Kraepelin E (1909-1915) Psychiatrie: Ein Lehrbuch für Studirende und Aerzte, 8th edn. Leipzig, Barth
148.
go back to reference Krstic D, Knuesel I (2013) The airbag problem—a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer’s disease. Acta Neuropathol Commun 1:62PubMedPubMedCentralCrossRef Krstic D, Knuesel I (2013) The airbag problem—a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer’s disease. Acta Neuropathol Commun 1:62PubMedPubMedCentralCrossRef
149.
go back to reference Kumar DKV, Eimer WA, Tanzi RE, Moir RD (2016) Alzheimer’s disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide. Neurodegener Dis Manag 6(5):345–348PubMedPubMedCentralCrossRef Kumar DKV, Eimer WA, Tanzi RE, Moir RD (2016) Alzheimer’s disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide. Neurodegener Dis Manag 6(5):345–348PubMedPubMedCentralCrossRef
150.
go back to reference Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K et al (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement 11(10):1180–1190PubMedCrossRef Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K et al (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement 11(10):1180–1190PubMedCrossRef
151.
go back to reference Lam B, Masellis M, Freedman M, Stuss DT, Black SE (2013) Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther 5(1):1PubMedPubMedCentralCrossRef Lam B, Masellis M, Freedman M, Stuss DT, Black SE (2013) Clinical, imaging, and pathological heterogeneity of the Alzheimer’s disease syndrome. Alzheimers Res Ther 5(1):1PubMedPubMedCentralCrossRef
152.
go back to reference Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45(12):1452–1458PubMedPubMedCentralCrossRef Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45(12):1452–1458PubMedPubMedCentralCrossRef
154.
go back to reference Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS et al (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72(4):578–586PubMedPubMedCentralCrossRef Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS et al (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 72(4):578–586PubMedPubMedCentralCrossRef
155.
go back to reference Lanoiselée H-M, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S et al (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLOS Med 14(3):e1002270PubMedPubMedCentralCrossRef Lanoiselée H-M, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S et al (2017) APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: a genetic screening study of familial and sporadic cases. PLOS Med 14(3):e1002270PubMedPubMedCentralCrossRef
156.
go back to reference Lee H-G, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321(3):823–829PubMedCrossRef Lee H-G, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321(3):823–829PubMedCrossRef
157.
go back to reference Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC et al (1996) The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 2:1146PubMedCrossRef Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC et al (1996) The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 2:1146PubMedCrossRef
158.
go back to reference Li N, Yu ZL, Wang L, Zheng YT, Jia JX, Wang Q et al (2010) Increased tau phosphorylation and beta amyloid in the hippocampus of mouse pups by early life lead exposure. Acta Biol Hung 61(2):123–134PubMedCrossRef Li N, Yu ZL, Wang L, Zheng YT, Jia JX, Wang Q et al (2010) Increased tau phosphorylation and beta amyloid in the hippocampus of mouse pups by early life lead exposure. Acta Biol Hung 61(2):123–134PubMedCrossRef
159.
go back to reference Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B et al (1996) Familial and sporadic Alzheimer’s disease: neuropathology cannot exclude a final common pathway. Neurology 46(2):406–412PubMedCrossRef Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B et al (1996) Familial and sporadic Alzheimer’s disease: neuropathology cannot exclude a final common pathway. Neurology 46(2):406–412PubMedCrossRef
160.
go back to reference Liu C-C, Zhao N, Fu Y, Wang N, Linares C, Tsai C-W et al (2017) ApoE4 accelerates early seeding of amyloid pathology. Neuron 96(5):1024.e3–1032.e3CrossRef Liu C-C, Zhao N, Fu Y, Wang N, Linares C, Tsai C-W et al (2017) ApoE4 accelerates early seeding of amyloid pathology. Neuron 96(5):1024.e3–1032.e3CrossRef
161.
go back to reference Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D et al (2017) Dementia prevention, intervention, and care. Lancet 390(10113):2673–2734PubMedCrossRef Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D et al (2017) Dementia prevention, intervention, and care. Lancet 390(10113):2673–2734PubMedCrossRef
162.
go back to reference Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS et al (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68(10):1257–1266PubMedPubMedCentralCrossRef Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS et al (2011) Longitudinal change of biomarkers in cognitive decline. Arch Neurol 68(10):1257–1266PubMedPubMedCentralCrossRef
163.
go back to reference Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF et al (2018) Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain 141(1):271–287PubMedCrossRef Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF et al (2018) Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain 141(1):271–287PubMedCrossRef
164.
go back to reference Lue L-F, Brachova L, Civin WH, Rogers J (1996) Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol 55(10):1083–1088PubMedCrossRef Lue L-F, Brachova L, Civin WH, Rogers J (1996) Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol 55(10):1083–1088PubMedCrossRef
166.
go back to reference Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W et al (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27(1):224–233PubMedCrossRef Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W et al (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27(1):224–233PubMedCrossRef
167.
go back to reference Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12):4245–4249PubMedCrossRefPubMedCentral Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12):4245–4249PubMedCrossRefPubMedCentral
168.
go back to reference McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V et al (2018) Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91(14):e1295–e1306PubMedCrossRefPubMedCentral McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V et al (2018) Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91(14):e1295–e1306PubMedCrossRefPubMedCentral
169.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944PubMedCrossRef McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944PubMedCrossRef
170.
go back to reference McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):263–269CrossRef McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc 7(3):263–269CrossRef
171.
go back to reference Miklossy J (2015) Historic evidence to support a causal relationship between spirochetal infections and Alzheimer’s disease. Front Aging Neurosci 7:46PubMedPubMedCentralCrossRef Miklossy J (2015) Historic evidence to support a causal relationship between spirochetal infections and Alzheimer’s disease. Front Aging Neurosci 7:46PubMedPubMedCentralCrossRef
172.
go back to reference Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41(4):479PubMedCrossRef Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41(4):479PubMedCrossRef
173.
174.
go back to reference Moller HJ, Graeber MB (1998) The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248(3):111–122PubMedCrossRef Moller HJ, Graeber MB (1998) The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248(3):111–122PubMedCrossRef
175.
go back to reference Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11PubMedCrossRef Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11PubMedCrossRef
176.
go back to reference Moreno-Treviño MG, Castillo-López J, Meester I (2015) Moving away from amyloid beta to move on in Alzheimer research. Front Aging Neurosci 7:2PubMedPubMedCentral Moreno-Treviño MG, Castillo-López J, Meester I (2015) Moving away from amyloid beta to move on in Alzheimer research. Front Aging Neurosci 7:2PubMedPubMedCentral
177.
go back to reference Morley J, Farr S, Banks W, Johnson SN, Yamada KA, Xu L (2008) A physiological role for amyloid beta protein: enhancement of learning and memory. J Alzheimers Dis 19(2):441–449CrossRef Morley J, Farr S, Banks W, Johnson SN, Yamada KA, Xu L (2008) A physiological role for amyloid beta protein: enhancement of learning and memory. J Alzheimers Dis 19(2):441–449CrossRef
178.
go back to reference Mormino EC, Papp KV, Rentz DM et al (2016) Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73(10):1185–1191PubMedPubMedCentralCrossRef Mormino EC, Papp KV, Rentz DM et al (2016) Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73(10):1185–1191PubMedPubMedCentralCrossRef
179.
go back to reference Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun 2(1):135PubMedPubMedCentral Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun 2(1):135PubMedPubMedCentral
180.
go back to reference Morris GP, Clark IA, Zinn R, Vissel B (2013) Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem 105:40–53PubMedCrossRef Morris GP, Clark IA, Zinn R, Vissel B (2013) Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem 105:40–53PubMedCrossRef
181.
go back to reference Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58(2):188–197PubMedCrossRef Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58(2):188–197PubMedCrossRef
182.
go back to reference Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C et al (2017) Detecting cognitive changes in preclinical Alzheimer’s disease: a review of its feasibility. Alzheimers Dement 13(4):468–492PubMedCrossRef Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C et al (2017) Detecting cognitive changes in preclinical Alzheimer’s disease: a review of its feasibility. Alzheimers Dement 13(4):468–492PubMedCrossRef
183.
go back to reference Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Cellini E et al (2003) Brain metabolic differences between sporadic and familial Alzheimer’s disease. Neurology 61(8):1138–1140PubMedCrossRef Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Cellini E et al (2003) Brain metabolic differences between sporadic and familial Alzheimer’s disease. Neurology 61(8):1138–1140PubMedCrossRef
184.
go back to reference Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky S et al (2015) Hippocampal plasticity during the progression of Alzheimer’s disease. Neuroscience 309:51–67PubMedCrossRef Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky S et al (2015) Hippocampal plasticity during the progression of Alzheimer’s disease. Neuroscience 309:51–67PubMedCrossRef
185.
go back to reference Mullane K, Williams M (2013) Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond? Biochem Pharmacol 85(3):289–305PubMedCrossRef Mullane K, Williams M (2013) Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond? Biochem Pharmacol 85(3):289–305PubMedCrossRef
186.
go back to reference Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J et al (2011) Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43(5):436–441PubMedPubMedCentralCrossRef Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J et al (2011) Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43(5):436–441PubMedPubMedCentralCrossRef
187.
go back to reference Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V et al (2018) High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554(7691):249–254CrossRefPubMed Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V et al (2018) High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554(7691):249–254CrossRefPubMed
188.
go back to reference Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362–381PubMedCrossRef Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362–381PubMedCrossRef
189.
go back to reference Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA et al (2011) Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121(5):571–587PubMedPubMedCentralCrossRef Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA et al (2011) Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121(5):571–587PubMedPubMedCentralCrossRef
190.
go back to reference Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA et al (2016) “New old pathologies”: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp Neurol 75(6):482–498PubMedCrossRefPubMedCentral Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA et al (2016) “New old pathologies”: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp Neurol 75(6):482–498PubMedCrossRefPubMedCentral
191.
go back to reference Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8):759–767CrossRefPubMed Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8):759–767CrossRefPubMed
192.
go back to reference O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O et al (2009) Neuropathologic studies of the baltimore longitudinal study of aging (BLSA). J Alzheimers Dis 18(3):665–675PubMedPubMedCentralCrossRef O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O et al (2009) Neuropathologic studies of the baltimore longitudinal study of aging (BLSA). J Alzheimers Dis 18(3):665–675PubMedPubMedCentralCrossRef
193.
go back to reference Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A (2011) Genetics of late-onset Alzheimer’s disease: update from the Alzgene database and analysis of shared pathways. Int J Alzheimers Dis 2011:832379PubMedPubMedCentral Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A (2011) Genetics of late-onset Alzheimer’s disease: update from the Alzgene database and analysis of shared pathways. Int J Alzheimers Dis 2011:832379PubMedPubMedCentral
194.
go back to reference Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15(7):673–684PubMedCrossRef Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15(7):673–684PubMedCrossRef
195.
go back to reference Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM et al (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313(19):1939–1949PubMedPubMedCentralCrossRef Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM et al (2015) Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313(19):1939–1949PubMedPubMedCentralCrossRef
196.
go back to reference Ossenkoppele R, Rabinovici GD, Smith R et al (2018) Discriminative accuracy of [18f]flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders. JAMA 320(11):1151–1162PubMedPubMedCentral Ossenkoppele R, Rabinovici GD, Smith R et al (2018) Discriminative accuracy of [18f]flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders. JAMA 320(11):1151–1162PubMedPubMedCentral
197.
go back to reference Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL et al (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139(5):1551–1567PubMedPubMedCentralCrossRef Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL et al (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139(5):1551–1567PubMedPubMedCentralCrossRef
198.
go back to reference Palasí A, Gutiérrez-Iglesias B, Alegret M, Pujadas F, Olabarrieta M, Liébana D et al (2015) Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol 262(5):1238–1246PubMedCrossRef Palasí A, Gutiérrez-Iglesias B, Alegret M, Pujadas F, Olabarrieta M, Liébana D et al (2015) Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol 262(5):1238–1246PubMedCrossRef
199.
go back to reference Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K et al (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 7(6):e38639PubMedPubMedCentralCrossRef Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K et al (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 7(6):e38639PubMedPubMedCentralCrossRef
200.
go back to reference Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N et al (2013) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 125(2):201–213PubMedCrossRef Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N et al (2013) Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 125(2):201–213PubMedCrossRef
201.
go back to reference Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I et al (2013) Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 136(8):2510–2526PubMedPubMedCentralCrossRef Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I et al (2013) Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 136(8):2510–2526PubMedPubMedCentralCrossRef
202.
go back to reference Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ (2012) Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69(2):223–229PubMedPubMedCentralCrossRef Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ (2012) Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 69(2):223–229PubMedPubMedCentralCrossRef
203.
go back to reference Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Muller ML et al (2015) Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord 30(7):928–935PubMedPubMedCentralCrossRef Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Muller ML et al (2015) Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord 30(7):928–935PubMedPubMedCentralCrossRef
204.
go back to reference Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci 30(45):14946–14954PubMedPubMedCentralCrossRef Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J Neurosci 30(45):14946–14954PubMedPubMedCentralCrossRef
205.
206.
go back to reference Podhorna J, Krahnke T, Shear M, Harrison JE (2016) Alzheimer’s Disease Assessment Scale–cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther 8(1):8PubMedPubMedCentralCrossRef Podhorna J, Krahnke T, Shear M, Harrison JE (2016) Alzheimer’s Disease Assessment Scale–cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies. Alzheimers Res Ther 8(1):8PubMedPubMedCentralCrossRef
207.
go back to reference Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S et al (2015) Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease. Acta Neuropathol Commun 3:14PubMedPubMedCentralCrossRef Pooler AM, Polydoro M, Maury EA, Nicholls SB, Reddy SM, Wegmann S et al (2015) Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease. Acta Neuropathol Commun 3:14PubMedPubMedCentralCrossRef
208.
209.
go back to reference Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M et al (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30(7):1026–1036PubMedPubMedCentralCrossRef Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M et al (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30(7):1026–1036PubMedPubMedCentralCrossRef
210.
go back to reference Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45(3):358–368PubMedCrossRef Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45(3):358–368PubMedCrossRef
211.
go back to reference Pujol-Pina R, Vilaprinyó-Pascual S, Mazzucato R, Arcella A, Vilaseca M, Orozco M et al (2015) SDS-PAGE analysis of Aβ oligomers is disserving research into Alzheimer’s disease: appealing for ESI-IM-MS. Sci Rep 5:14809PubMedPubMedCentralCrossRef Pujol-Pina R, Vilaprinyó-Pascual S, Mazzucato R, Arcella A, Vilaseca M, Orozco M et al (2015) SDS-PAGE analysis of Aβ oligomers is disserving research into Alzheimer’s disease: appealing for ESI-IM-MS. Sci Rep 5:14809PubMedPubMedCentralCrossRef
212.
go back to reference Puzzo D, Gulisano W, Arancio O, Palmeri A (2015) The keystone of Alzheimer pathogenesis might be sought in Abeta physiology. Neuroscience 307:26–36PubMedCrossRef Puzzo D, Gulisano W, Arancio O, Palmeri A (2015) The keystone of Alzheimer pathogenesis might be sought in Abeta physiology. Neuroscience 307:26–36PubMedCrossRef
213.
go back to reference Quiroz YT, Sperling RA, Norton DJ et al (2018) Association between amyloid and tau accumulation in young adults with autosomal dominant alzheimer disease. JAMA Neurol 75(5):548–556PubMedCrossRefPubMedCentral Quiroz YT, Sperling RA, Norton DJ et al (2018) Association between amyloid and tau accumulation in young adults with autosomal dominant alzheimer disease. JAMA Neurol 75(5):548–556PubMedCrossRefPubMedCentral
214.
go back to reference Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N et al (2017) Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimers Dement Transl Res Clin Interv 3(1):83–91CrossRef Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N et al (2017) Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimers Dement Transl Res Clin Interv 3(1):83–91CrossRef
215.
go back to reference Raghavan NS, Brickman AM, Andrews H, Manly JJ, Schupf N, Lantigua R et al (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer’s disease. Ann Clin Transl Neurol 5(7):832–842PubMedPubMedCentralCrossRef Raghavan NS, Brickman AM, Andrews H, Manly JJ, Schupf N, Lantigua R et al (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer’s disease. Ann Clin Transl Neurol 5(7):832–842PubMedPubMedCentralCrossRef
216.
go back to reference Raisanen U, Bekkers MJ, Boddington P, Sarangi S, Clarke A (2006) The causation of disease—the practical and ethical consequences of competing explanations. Med Health Care Philos 9(3):293–306PubMedCrossRef Raisanen U, Bekkers MJ, Boddington P, Sarangi S, Clarke A (2006) The causation of disease—the practical and ethical consequences of competing explanations. Med Health Care Philos 9(3):293–306PubMedCrossRef
217.
go back to reference Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA (2015) Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology 85(10):898–904PubMedPubMedCentralCrossRef Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA (2015) Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology 85(10):898–904PubMedPubMedCentralCrossRef
218.
go back to reference Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V et al (2018) Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99(1):64.e7–82.e7CrossRef Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V et al (2018) Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. Neuron 99(1):64.e7–82.e7CrossRef
219.
go back to reference Riudavets MA, Iacono D, Resnick SM, O’Brien R, Zonderman AB, Martin LJ et al (2007) Resistance to Alzheimer’s pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 28(10):1484–1492PubMedPubMedCentralCrossRef Riudavets MA, Iacono D, Resnick SM, O’Brien R, Zonderman AB, Martin LJ et al (2007) Resistance to Alzheimer’s pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 28(10):1484–1492PubMedPubMedCentralCrossRef
221.
go back to reference Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80(19):1784–1791PubMedPubMedCentralCrossRef Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D et al (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80(19):1784–1791PubMedPubMedCentralCrossRef
222.
go back to reference Roth M, Tomlinson BE, Blessed G (1966) Correlation between scores for dementia and counts of ‘senile plaques’ in cerebral grey matter of elderly subjects. Nature 209:109PubMedCrossRef Roth M, Tomlinson BE, Blessed G (1966) Correlation between scores for dementia and counts of ‘senile plaques’ in cerebral grey matter of elderly subjects. Nature 209:109PubMedCrossRef
223.
go back to reference Rothschild D, Trainor MA (1937) Pathologic changes in senile psychoses and their psychobiologic significance. Am J Psychiatry 93(4):757–788CrossRef Rothschild D, Trainor MA (1937) Pathologic changes in senile psychoses and their psychobiologic significance. Am J Psychiatry 93(4):757–788CrossRef
224.
go back to reference Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31(8):1275–1283PubMedCrossRef Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31(8):1275–1283PubMedCrossRef
225.
go back to reference Rub U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW (2017) Alzheimer’s disease: characterization of the brain sites of the initial tau cytoskeletal pathology will improve the success of novel immunological anti-tau treatment approaches. J Alzheimers Dis 57(3):683–696PubMedCrossRef Rub U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW (2017) Alzheimer’s disease: characterization of the brain sites of the initial tau cytoskeletal pathology will improve the success of novel immunological anti-tau treatment approaches. J Alzheimers Dis 57(3):683–696PubMedCrossRef
226.
go back to reference Ryan MM, Morris GP, Mockett BG, Bourne K, Abraham WC, Tate WP et al (2013) Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genom 14(1):376CrossRef Ryan MM, Morris GP, Mockett BG, Bourne K, Abraham WC, Tate WP et al (2013) Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genom 14(1):376CrossRef
227.
go back to reference Ryan NS, Rossor MN (2010) Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomark Med 4(1):99–112PubMedCrossRef Ryan NS, Rossor MN (2010) Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomark Med 4(1):99–112PubMedCrossRef
228.
go back to reference Ryan NS, Rossor MN, Fox NC (2015) Alzheimer’s disease in the 100 years since Alzheimer’s death. Brain 138(12):3816–3821PubMedCrossRef Ryan NS, Rossor MN, Fox NC (2015) Alzheimer’s disease in the 100 years since Alzheimer’s death. Brain 138(12):3816–3821PubMedCrossRef
229.
go back to reference Sá F, Pinto P, Cunha C, Lemos R, Letra L, Simões M et al (2012) Differences between early and late-onset Alzheimer’s disease in neuropsychological tests. Front Neurol 3:81PubMedPubMedCentralCrossRef Sá F, Pinto P, Cunha C, Lemos R, Letra L, Simões M et al (2012) Differences between early and late-onset Alzheimer’s disease in neuropsychological tests. Front Neurol 3:81PubMedPubMedCentralCrossRef
230.
go back to reference Saito T, Matsuba Y, Yamazaki N, Hashimoto S, Saido TC (2016) Calpain activation in Alzheimer’s model mice is an artifact of APP and presenilin overexpression. J Neurosci 36(38):9933–9936PubMedPubMedCentralCrossRef Saito T, Matsuba Y, Yamazaki N, Hashimoto S, Saido TC (2016) Calpain activation in Alzheimer’s model mice is an artifact of APP and presenilin overexpression. J Neurosci 36(38):9933–9936PubMedPubMedCentralCrossRef
231.
go back to reference Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333PubMedPubMedCentralCrossRef Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333PubMedPubMedCentralCrossRef
233.
go back to reference SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL (2011) Alzheimer disease pathology in subjects without dementia in two studies of aging: the nun study and the adult changes in thought study. J Neuropathol Exp Neurol 70(10):832–840PubMedCrossRef SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL (2011) Alzheimer disease pathology in subjects without dementia in two studies of aging: the nun study and the adult changes in thought study. J Neuropathol Exp Neurol 70(10):832–840PubMedCrossRef
234.
go back to reference Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B et al (2017) APP mouse models for Alzheimer’s disease preclinical studies. EMBO J 36(17):2473–2487PubMedPubMedCentralCrossRef Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B et al (2017) APP mouse models for Alzheimer’s disease preclinical studies. EMBO J 36(17):2473–2487PubMedPubMedCentralCrossRef
235.
go back to reference Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360(22):2302–2309PubMedCrossRef Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360(22):2302–2309PubMedCrossRef
237.
go back to reference Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet 388(10043):505–517PubMedCrossRef Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet 388(10043):505–517PubMedCrossRef
238.
go back to reference Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197–2204PubMedCrossRef Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197–2204PubMedCrossRef
239.
go back to reference Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2):200–208PubMedPubMedCentralCrossRef Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66(2):200–208PubMedPubMedCentralCrossRef
240.
go back to reference Schöll M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S et al (2015) Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep 5:16404PubMedPubMedCentralCrossRef Schöll M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S et al (2015) Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep 5:16404PubMedPubMedCentralCrossRef
241.
go back to reference Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89(5):971–982PubMedPubMedCentralCrossRef Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89(5):971–982PubMedPubMedCentralCrossRef
242.
go back to reference Scott G, Ramlackhansingh AF, Edison P, Hellyer P, Cole J, Veronese M et al (2016) Amyloid pathology and axonal injury after brain trauma. Neurology 86(9):821–828PubMedPubMedCentralCrossRef Scott G, Ramlackhansingh AF, Edison P, Hellyer P, Cole J, Veronese M et al (2016) Amyloid pathology and axonal injury after brain trauma. Neurology 86(9):821–828PubMedPubMedCentralCrossRef
243.
245.
go back to reference Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gómez-Isla T, Betensky RA et al (2014) Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 75(4):597–601PubMedPubMedCentralCrossRef Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gómez-Isla T, Betensky RA et al (2014) Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 75(4):597–601PubMedPubMedCentralCrossRef
246.
go back to reference Seshadri S, Fitzpatrick AL, Arfan Ikram M, DeStefano AL, Gudnason V, Boada M et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer’s disease. J Am Med Assoc 303(18):1832–1840CrossRef Seshadri S, Fitzpatrick AL, Arfan Ikram M, DeStefano AL, Gudnason V, Boada M et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer’s disease. J Am Med Assoc 303(18):1832–1840CrossRef
247.
go back to reference Shea Y-F, Chu L-W, Chan AO-K, Ha J, Li Y, Song Y-Q (2016) A systematic review of familial Alzheimer’s disease: differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Formos Med Assoc 115(2):67–75PubMedCrossRef Shea Y-F, Chu L-W, Chan AO-K, Ha J, Li Y, Song Y-Q (2016) A systematic review of familial Alzheimer’s disease: differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Formos Med Assoc 115(2):67–75PubMedCrossRef
248.
go back to reference Shulman JM, Chen K, Keenan BT, Chibnik LB, Fleisher A, Thiyyagura P et al (2013) Genetic susceptibility for Alzheimer’s disease neuritic plaque pathology. JAMA Neurol 70(9):1150–1157PubMedPubMedCentralCrossRef Shulman JM, Chen K, Keenan BT, Chibnik LB, Fleisher A, Thiyyagura P et al (2013) Genetic susceptibility for Alzheimer’s disease neuritic plaque pathology. JAMA Neurol 70(9):1150–1157PubMedPubMedCentralCrossRef
249.
go back to reference Smith MA, Atwood CS, Joseph JA, Perry G (2002) Predicting the failure of amyloid-beta vaccine. Lancet 359(9320):1864–1865PubMedCrossRef Smith MA, Atwood CS, Joseph JA, Perry G (2002) Predicting the failure of amyloid-beta vaccine. Lancet 359(9320):1864–1865PubMedCrossRef
250.
go back to reference Snowdon DA (1997) Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist 37(2):150–156PubMedCrossRef Snowdon DA (1997) Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist 37(2):150–156PubMedCrossRef
251.
go back to reference Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10):813–817PubMedCrossRef Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10):813–817PubMedCrossRef
252.
go back to reference Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M et al (2014) Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 275(3):229–250PubMedPubMedCentralCrossRef Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M et al (2014) Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 275(3):229–250PubMedPubMedCentralCrossRef
253.
go back to reference Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G (2014) The dark sides of amyloid in Alzheimer’s disease pathogenesis. FEBS Lett 588(5):641–652PubMedCrossRef Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G (2014) The dark sides of amyloid in Alzheimer’s disease pathogenesis. FEBS Lett 588(5):641–652PubMedCrossRef
254.
255.
go back to reference Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292PubMedPubMedCentralCrossRef Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292PubMedPubMedCentralCrossRef
256.
258.
go back to reference Stites SD, Milne R, Karlawish J (2018) Advances in Alzheimer’s imaging are changing the experience of Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit 10:285–300 Stites SD, Milne R, Karlawish J (2018) Advances in Alzheimer’s imaging are changing the experience of Alzheimer’s disease. Alzheimers Dement Diagn Assess Dis Monit 10:285–300
259.
go back to reference Stratmann K, Heinsen H, Korf H-W, Del Turco D, Ghebremedhin E, Seidel K et al (2016) Precortical phase of Alzheimer’s disease (AD)-related tau cytoskeletal pathology. Brain Pathol (Zurich, Switz) 26(3):371–386CrossRef Stratmann K, Heinsen H, Korf H-W, Del Turco D, Ghebremedhin E, Seidel K et al (2016) Precortical phase of Alzheimer’s disease (AD)-related tau cytoskeletal pathology. Brain Pathol (Zurich, Switz) 26(3):371–386CrossRef
260.
go back to reference Sun L, Zhou R, Yang G, Shi Y (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci 114(4):E476–E485PubMedCrossRef Sun L, Zhou R, Yang G, Shi Y (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci 114(4):E476–E485PubMedCrossRef
261.
go back to reference Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E et al (2015) Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol 11(8):457–470PubMedPubMedCentralCrossRef Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E et al (2015) Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol 11(8):457–470PubMedPubMedCentralCrossRef
262.
go back to reference Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J et al (2018) Early- and late-onset Alzheimer disease: are they the same entity? Neurología (Engl Ed) 33(4):244–253CrossRef Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J et al (2018) Early- and late-onset Alzheimer disease: are they the same entity? Neurología (Engl Ed) 33(4):244–253CrossRef
264.
go back to reference Terry RD (2000) Do neuronal inclusions kill the cell?. Springer Vienna, ViennaCrossRef Terry RD (2000) Do neuronal inclusions kill the cell?. Springer Vienna, ViennaCrossRef
265.
go back to reference Terry RD (2006) Alzheimer’s disease and the aging brain. J Geriatr Psychiatry Neurol 19(3):125–128PubMedCrossRef Terry RD (2006) Alzheimer’s disease and the aging brain. J Geriatr Psychiatry Neurol 19(3):125–128PubMedCrossRef
266.
go back to reference Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572–580PubMedCrossRef Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4):572–580PubMedCrossRef
267.
go back to reference Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer’s disease. Arch Gen Psychiatry 67(7):739–748PubMedPubMedCentralCrossRef Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer’s disease. Arch Gen Psychiatry 67(7):739–748PubMedPubMedCentralCrossRef
268.
go back to reference Thiel A, Cechetto DF, Heiss WD, Hachinski V, Whitehead SN (2014) Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke 45(9):2825–2829PubMedCrossRef Thiel A, Cechetto DF, Heiss WD, Hachinski V, Whitehead SN (2014) Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke 45(9):2825–2829PubMedCrossRef
269.
go back to reference Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7(2):331–356PubMedCrossRef Tomlinson BE, Blessed G, Roth M (1968) Observations on the brains of non-demented old people. J Neurol Sci 7(2):331–356PubMedCrossRef
270.
go back to reference Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11(3):205–242PubMedCrossRef Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11(3):205–242PubMedCrossRef
271.
go back to reference Trans BS (2011) The amyloid cascade hypothesis has misled the pharmaceutical industry. Biochem Soc Trans 39(4):920–923CrossRef Trans BS (2011) The amyloid cascade hypothesis has misled the pharmaceutical industry. Biochem Soc Trans 39(4):920–923CrossRef
272.
go back to reference Tse KH, Herrup K (2017) Re-imagining Alzheimer’s disease—the diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem 143(4):432–444PubMedCrossRef Tse KH, Herrup K (2017) Re-imagining Alzheimer’s disease—the diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem 143(4):432–444PubMedCrossRef
273.
go back to reference Tzeng N-S, Chung C-H, Lin F-H, Chiang C-P, Yeh C-B, Huang S-Y et al (2018) Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15(2):417–429PubMedCrossRefPubMedCentral Tzeng N-S, Chung C-H, Lin F-H, Chiang C-P, Yeh C-B, Huang S-Y et al (2018) Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15(2):417–429PubMedCrossRefPubMedCentral
274.
go back to reference Udeochu J, Sayed FA, Gan L (2018) TREM2 and amyloid beta: a love–hate relationship. Neuron 97(5):991–993PubMedCrossRef Udeochu J, Sayed FA, Gan L (2018) TREM2 and amyloid beta: a love–hate relationship. Neuron 97(5):991–993PubMedCrossRef
275.
go back to reference Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2015) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421PubMedPubMedCentralCrossRef Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2015) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421PubMedPubMedCentralCrossRef
276.
go back to reference van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F et al (2012) Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer’s disease. J Alzheimers Dis 29(2):319–327PubMedCrossRef van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F et al (2012) Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer’s disease. J Alzheimers Dis 29(2):319–327PubMedCrossRef
277.
go back to reference Vasconcelos B, Stancu IC, Buist A, Bird M, Wang P, Vanoosthuyse A et al (2016) Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Acta Neuropathol 131(4):549–569PubMedPubMedCentralCrossRef Vasconcelos B, Stancu IC, Buist A, Bird M, Wang P, Vanoosthuyse A et al (2016) Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Acta Neuropathol 131(4):549–569PubMedPubMedCentralCrossRef
278.
go back to reference Verheijen J, Sleegers K (2018) Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet 34(6):434–447PubMedCrossRef Verheijen J, Sleegers K (2018) Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet 34(6):434–447PubMedCrossRef
279.
go back to reference Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC (2018) Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(4):225–236PubMedCrossRef Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC (2018) Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(4):225–236PubMedCrossRef
280.
go back to reference Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69(1):181–192PubMedPubMedCentralCrossRef Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69(1):181–192PubMedPubMedCentralCrossRef
281.
282.
go back to reference Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T et al (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125(4):549–564PubMedCrossRef Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T et al (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125(4):549–564PubMedCrossRef
283.
go back to reference Watts JC, Prusiner SB (2018) Beta-amyloid prions and the pathobiology of Alzheimer’s disease. Cold Spring Harb Perspect Med 8(5) Watts JC, Prusiner SB (2018) Beta-amyloid prions and the pathobiology of Alzheimer’s disease. Cold Spring Harb Perspect Med 8(5)
284.
go back to reference Whitehouse PJ, Daniel George MS (2008) The myth of Alzheimer’s: what you aren’t being told about today’s most dreaded diagnosis. St. Martin’s Press, New York Whitehouse PJ, Daniel George MS (2008) The myth of Alzheimer’s: what you aren’t being told about today’s most dreaded diagnosis. St. Martin’s Press, New York
285.
go back to reference Wilson D (2014) Quantifying the quiet epidemic: diagnosing dementia in late 20th-century Britain. Hist Hum Sci 27(5):126–146CrossRef Wilson D (2014) Quantifying the quiet epidemic: diagnosing dementia in late 20th-century Britain. Hist Hum Sci 27(5):126–146CrossRef
286.
go back to reference Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA (2010) Neurodegenerative basis of age-related cognitive decline (e-Pub ahead of print)(CME). Neurology 75(12):1070–1078PubMedPubMedCentralCrossRef Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA (2010) Neurodegenerative basis of age-related cognitive decline (e-Pub ahead of print)(CME). Neurology 75(12):1070–1078PubMedPubMedCentralCrossRef
287.
go back to reference Wingo TS, Lah JJ, Levey AI, Cutler DJ (2012) Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol 69(1):59–64PubMedCrossRef Wingo TS, Lah JJ, Levey AI, Cutler DJ (2012) Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol 69(1):59–64PubMedCrossRef
288.
go back to reference Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J NeuroImmune Pharmacol 4(2):200–212PubMedCrossRef Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J NeuroImmune Pharmacol 4(2):200–212PubMedCrossRef
290.
go back to reference Yashin AI, Fang F, Kovtun M, Wu D, Duan M, Arbeev K et al (2018) Hidden heterogeneity in Alzheimer’s disease: insights from genetic association studies and other analyses. Exp Gerontol 107:148–160PubMedCrossRef Yashin AI, Fang F, Kovtun M, Wu D, Duan M, Arbeev K et al (2018) Hidden heterogeneity in Alzheimer’s disease: insights from genetic association studies and other analyses. Exp Gerontol 107:148–160PubMedCrossRef
291.
go back to reference Yin R-H, Yu J-T, Tan L (2015) The role of SORL1 in Alzheimer’s disease. Mol Neurobiol 51(3):909–918PubMedCrossRef Yin R-H, Yu J-T, Tan L (2015) The role of SORL1 in Alzheimer’s disease. Mol Neurobiol 51(3):909–918PubMedCrossRef
292.
go back to reference Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 73(1):60–67PubMedPubMedCentralCrossRef Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 73(1):60–67PubMedPubMedCentralCrossRef
293.
go back to reference Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA et al (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153(3):707–720PubMedPubMedCentralCrossRef Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA et al (2013) Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153(3):707–720PubMedPubMedCentralCrossRef
294.
go back to reference Zhu X-C, Tan L, Wang H-F, Jiang T, Cao L, Wang C et al (2015) Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Ann Transl Med 3(3):38PubMedPubMedCentral Zhu X-C, Tan L, Wang H-F, Jiang T, Cao L, Wang C et al (2015) Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Ann Transl Med 3(3):38PubMedPubMedCentral
Metadata
Title
Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease
Authors
Gary P. Morris
Ian A. Clark
Bryce Vissel
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Acta Neuropathologica / Issue 5/2018
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-018-1918-8

Other articles of this Issue 5/2018

Acta Neuropathologica 5/2018 Go to the issue